Background {#Sec1}
==========

Chronic obstructive pulmonary disease (COPD) is the third leading cause of death in the United States \[[@CR1]\] and is identified by airflow limitation and/or obstruction. The severity of COPD is assessed by forced expiratory volume in 1 s (FEV~1~%) predicted values at post bronchodilator \[[@CR2]\]. The pulmonary function test (PFT)-based FEV~1~ and forced vital capacity (FVC) values are highly recommended to assess the global alteration of lung, but they do not correlate well with symptoms \[[@CR3]\]. In addition, PFTs do not reveal local structural and functional alterations, which are essential in examining the heterogeneity of COPD phenotypes. Thus, the ability to quantify these alterations at multiple scales during COPD progression is necessary to characterize COPD phenotypes.

A multicenter study of COPD, i.e., Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS) \[[@CR2]\] acquired QCT scans at total lung capacity (TLC) and residual volume (RV) \[[@CR4]\]. This is an integral part of the multicenter study to find structural and functional phenotypes. A recent advance of quantitative medical imaging and data analysis techniques allows for derivation of QCT imaging-based metrics, leading to identification of statistically stable clusters/phenotypes. For instance, using only QCT imaging-based variables, Choi et al. \[[@CR5]\] derived clinically meaningful asthmatic sub-groups, being potentially useful in developing clusters-specific treatments. Furthermore, Haghighi et al. \[[@CR6]\] expanded the QCT imaging-based clustering approach to identify homogenous clusters within current smokers from SPIROMICS. In this study, we hypothesize that QCT-based imaging metrics could be used to identify distinct COPD former smoker sub-groups with clinically meaningful characteristics, subsequently adding insights to the previous study of current smokers \[[@CR6]\]. Shaker et al. \[[@CR7]\] and Zach et al. \[[@CR8]\] reported that former smokers had significantly higher % low-attenuation areas (%LAAs) on inspiration and expiration CT scans (for emphysema and air trapping measures) than current smokers. This is possibly due to parenchymal inflammation in current smokers serving to mask CT-based indices relative to former smokers \[[@CR6], [@CR7]\]. Therefore, we divided the subjects into former and current smokers to independently assess phenotypes between these two groups and report on the former smokers in this work.

With the aid of machine learning techniques, QCT imaging-based metrics have been used to find homogeneous sub-groups of COPD subjects. As an example, Bodduluri et al. \[[@CR9]\] have employed image registration-based metrics to discriminate COPD subjects from non-COPD subjects. The study demonstrated the potential of registration-based variables to characterize COPD phenotypes, but this study was limited in supervised learning. In regards to unsupervised learning methods, there have been several efforts to identify COPD sub-groups, but they employed either clinical data-only or a mix of clinical and CT data together \[[@CR10]--[@CR12]\] as we focus on imaging-only parameters to identify clusters. Although it would be possible to add clinical/physiological/biological measures into our cluster analysis, we used only imaging-based features to focus features of airway structure and lung function. Once established, our clusters were evaluated for their clinical, physiological, or biological measures. The associations between imaging-only clusters and the non-imaging phenotypes provide a validation of the ability of imaging metrics to characterize clinically meaningful phenotypes. Choi et al. \[[@CR5]\] pioneered the use of unsupervised cluster analysis using CT image data acquired by the Severe Asthma Research Program (SARP) to identify four asthmatic clusters. Their approach accounted for inter-site and inter-subject variations, enabling an analysis of large data sets acquired by multiple centers. Furthermore, Choi et al. \[[@CR13]\] successfully identified imaging-based structural and functional features that differentiate asthmatics and COPD patients with chronic functional alteration.

In this study, we adopted the approach by Choi et al. \[[@CR5]\]. In addition to the existing imaging-based metrics developed for asthma, we introduced several new metrics to account for tissue alterations and emphysematous lung \[[@CR5], [@CR6]\]. A comprehensive set of imaging-based metrics were transformed to the principal component domain, and a cluster analysis was performed to explore possible COPD phenotypes of former smokers. The former smokers-clusters were then evaluated in association with severity, GOLD stages \[[@CR14]\], sex, BMI and biomarkers, such as neutrophil counts, leukocyte (WBC) count and matrix metalloproteinase (MMP-3). We then compared the cluster membership of former smokers in this study with that of current smokers presented in our previous study \[[@CR6]\].

Methods {#Sec2}
=======

Human subject data and QCT imaging {#Sec3}
----------------------------------

We analyzed a total of 758 SPIROMICS subjects containing an extensive set of biomarkers. In our analysis, we hypothesized that smoking status may have effects on CT measures of former and current smokers \[[@CR7], [@CR8]\]. The hypothesis was further consolidated by performing a combined analysis and finding that a mix of both groups cannot provide adequate cluster stability. Hence, we excluded current smokers, so that a total of 406 formers smokers remained. The healthy never smokers without COPD were considered as healthy controls and were not included in the clustering analysis. PFTs were performed for all subjects pre- and post- bronchodilator, and CT was performed post-bronchodilator. Table [1](#Tab1){ref-type="table"} shows the demographic and PFT measures based on each stratum. Former smokers with post-bronchodilator FEV~1~/FVC \> 0.7 were grouped in stratum 2, and former smokers in strata 3 and 4 had post-bronchodilator FEV~1~/FVC \< 0.7, with FEV~1~ \> 50% in stratum 3 and FEV~1~ \< 50% in stratum 4, respectively \[[@CR2]\].Table 1Demography, baseline (Pre-bronchodilator) and maximal (Post-bronchodilator) pulmonary function tests for 105 Stratum 1 (healthy), 119 Stratum 2, 184 Stratum 3 and 103 Stratum 4 subjectsStratum 1 (Healthy)Stratum 2Stratum 3Stratum 4*P* value*N* = 69*N* = 119*N* = 184*N* = 103*Demography* Age, yrs58.6(10.5)65.1(7.5)69.1(6.4)65.2(7.5)\<  0.0001 BMI, kg/m^2^28.4(5.2)29.5(4.8)28.4(4.6)27.0(4.7)\<  0.0001 Sex, (Male/Female %)42/5851.3/48.762.5/37.557.3/42.7= 0.02 Race, Caucasian/ African American/ Other (%)62.3/26.1/ 11.681.5/12.6/ 5.988.0 /7.1/ 4.985.4 /9.7/ 4.9\<  0.0001~*Baseline\ lung\ function*~ ^a^ FEV~1~% predicted98(13)91(14)67(16)28(8)\<  0.0001 FVC % predicted98(11)94(13)91(16)67(15)\<  0.0001 FEV~1~/FVC × 10078(6)74(6)55(9)32(9)\<  0.0001~*Maximal\ lung\ function*~ ^b^ FEV~1~% predicted102(12)97(14)76(15)34(10)\<  0.0001 FVC % predicted98(11)95(13)99(15)76(17)\<  0.0001 FEV~1~/FVC × 10081(6)78(5)57(8)34(9)\<  0.0001Values expressed as mean (SD) or number (%). Kruskal-Wallis and chi-square tests were performed for continuous and categorical variables^a^Baseline (Pre-bronchodilator) values with greater than six hours withhold of bronchodilators. ^b^Maximal (Post-bronchodilator) values after six to eight puffs of albuterol

Two QCT scans at TLC and RV were acquired by multiple imaging centers in the NIH-funded SPIROMICS multicenter research study \[[@CR4]\]. The CT imaging protocols were approved by each center's institutional review boards (IRB). All QCT scans were obtained with post-bronchodilator. They were segmented with an automated commercial airway/lung segmentation software (Apollo 2.0, VIDA Diagnostics), and registered with a non-rigid mass-preserving imaging registration technique \[[@CR15], [@CR16]\].

Derivation of QCT imaging-based metrics {#Sec4}
---------------------------------------

A total of 75 multiscale imaging-based variables were extracted to derive principal components (Fig. [1](#Fig1){ref-type="fig"}). The segmental variables included bifurcation angle (*θ*), airway circularity (*Cr*), wall thickness (WT) and hydraulic diameter (*D*~h~), where each variable indicated alteration of skeletal structure, alteration of airway shape, wall thickening and luminal narrowing, respectively. The sizes of WT and *D*~h~ were normalized by tracheal WT and average diameter (*D*~ave~) predicted from healthy subjects \[[@CR5]\], being denoted by WT\* and *D*~h~\*, to eliminate inter-subject variability due to age, sex, and height. The four segmental variables were extracted from ten local regions to reflect characteristics of regional alterations. A detailed derivation of the above structural variables can be found in reference \[[@CR17]\].Fig. 1An expanded set of imaging-based metrics including emphysema percentage, tissue fraction at TLC and RV. **a** Inspirational image-based local structures: *θ*, Cr, WT\*, and D~h~\*. **b** Expiration image-based global and lobar function: AirT%. **c** Inspiration image-based global and lobar function: Emph%. **d** Global structure:. **e** Registration-based global and lobar functions:.

We further derived both strain-based and density-based functional metrics with the aid of image registration that matched two QCT images at TLC and RV. The strain-based variables included fractional air volume change (ΔV~air~^F^), the determinant of Jacobian (Jacobian), and anisotropic deformation index (ADI). These are estimates of regional ventilation, local volume change, and preferential local lung deformation respectively \[[@CR18], [@CR19]\]. Next, the density-based functional metrics included functional small airway disease percentage (fSAD%) and emphysema percentage (Emph%) to characterize the portions of small airway narrowing/closure and emphysematous lung, respectively. This approach was devised to dissociate emphysematous region from air-trapping region, previously proposed by Galban et al. \[[@CR20]\]. In order to eliminate inter-site variation, we employed a fraction-based fSAD% and Emph% using 90 and 98.5% air-fraction as the threshold, instead of using the density threshold of − 856 and − 950, respectively \[[@CR21]\]. We further added two more imaging-based metrics that measure tissue fraction \[[@CR13], [@CR22]\] at TLC and RV (*β*~tissue~^TLC^ and *β*~tissue~^RV^). The tissue fractions measure the portion of tissue volume in each voxel. These are supplementary metrics for Emph% and fSAD%, because *β*~tissue~^TLC^ decreases if tissue destruction is captured and *β*~tissue~^RV^ decreases if air fraction increases due to air-trapping.

In addition, we included global imaging-based metrics such as the ratio of apical-basal distance over ventral-dorsal distance at TLC (lung shape), the ratio of air-volume changes in upper lobes to those in middle and lower lobes between TLC and RV (U/(M + L)\|v), fSAD%, Emph%, *β*~tissue~^TLC^ and *β*~tissue~^RV^, Jacobian and ADI in the whole lung. Overall, there were 32 local/segmental structural variables, 35 lobar structural variables and 8 global structural variables.

Cluster and statistical analysis {#Sec5}
--------------------------------

Raw imaging data were scaled with standard scaler, and a principal component analysis was performed to derive linearly uncorrelated variables, so-called principal components (PCs). To obtain an optimal number of PCs, a parallel analysis \[[@CR23]\] with random uncorrelated data was adopted. The analysis led to the number of 7 as an optimal choice of PCs (Additional file [1](#MOESM1){ref-type="media"}: Figure S1).

Using the 7 derived PCs, to find the optimal clustering method and number, we then assessed internal properties including connectivity, average Silhouette width and Dunn indices \[[@CR24]\] for three different clustering methods, i.e., hierarchical, K-means, and Gaussian finite mixture model-based methods. Connectivity, average Silhouette width and Dunn indices measure the inverse of *i*^th^ nearest neighbors which is not assigned to the same cluster, how tightly grouped all the points in the cluster are, and the ratio between the minimal inter-cluster distance to maximal intra-cluster distance, respectively. Thus smaller connectivity and larger Silhouette width and Dunn index indicate better clustering properties. First, K-means method was found to be a good clustering method for current data based on connectivity, and average Silhouette width (Additional file [2](#MOESM2){ref-type="media"}: Figure S2a). Dunn criteria then suggested that the number of 4 is an optimal choice in using K-means. To further test stability of the clustering membership, a nonparametric bootstrap analysis was performed with 200 bootstrapped data sets. The mean of Jaccard similarity coefficients, defined by the size of intersection divided by the size of the union between clusters \[[@CR25]\], was computed to find the optimal cluster number and clustering approach (Additional file [2](#MOESM2){ref-type="media"}: Figure S2b).

Kruskal-Wallis and chi-square tests were performed to compare differences of continuous and categorical variables, respectively. The reported *P* values were significant, if any one group is statistically different from one group or more. We then performed association tests of imaging-based clusters with demographic and clinical variables to investigate the clinical relevance of current clusters.

Results {#Sec6}
=======

Structural and functional features of imaging-based clusters {#Sec7}
------------------------------------------------------------

Cluster analysis identified four stable \[[@CR6]\] imaging-based clusters with the sizes of 100, 80, 141 and 85, respectively (Table [2](#Tab2){ref-type="table"}, and Fig. [2](#Fig2){ref-type="fig"}). Five major variables with higher Wilk's *λ* values which best describe the four clusters were selected with a stepwise forward variable selection technique using Wilk's *λ* criterion \[[@CR26]\]. Note that the clusters were differentiated predominantly with whole lung (total) parenchymal metrics including β~tissue~ at RV and TLC, Jacobian, Emph% and fSAD%. Overall whole lung Emph% and fSAD% increased with increasing cluster number. It was noted that Emph% and fSAD% in Cluster 2 fell within the similar range with healthy subjects (Fig. [3](#Fig3){ref-type="fig"}).Table 2Major imaging-based features selected by Wilk's *λ* value of a stepwise forward variable selection method in four imaging-based clusters and healthy subjects (stratum 1)VariableRegionWilk's\
λ valueCluster 1\
(*N* = 100)Cluster 2\
(*N* = 80)Cluster 3\
(*N* = 141)Cluster 4\
(*N* = 85)*P* valueStratum 1\
(*N* = 69)β~tissue~^RV^Total0.2860.240(0.041)0.245(0.041)0.172(0.026)0.110(0.020)\< 0.00010.264(0.054)JacobianTotal0.1452.16(0.259)1.67(0.200)1.63(0.201)1.32(0.147)\< 0.00012.11(0.378)Emph%Total0.1165.8(0.058)2.4(0.026)10.4(0.073)25.0(0.110)\< 0.00010.024(0.028)fSAD%Total0.0938.7(0.065)7.5(0.055)23.5(0.086)36.8(0.074)\< 0.00010.050(0.052)β~tissue~^TLC^Total0.0800.109(0.015)0.142(0.019)0.103(0.014)0.081(0.014)\< 0.00010.122(0.03)Values expressed as mean (SD). Full names of each variable or region were described in *Abbreviations used*Fig. 2A summary of imaging and clinical characteristics between clustersFig. 3**a** Percentage of emphysema (Emph%) for four clusters and the healthy control group (green). † *P* \> 0.05 between clusters 1, 2, 3 and the healthy group. *P* \< 0.05 between Cluster 4 and other groups for all pairwise comparisons **b** Percentage of small airway disease (fSAD%) for four clusters and the healthy control group (green). ‡ *P* \< 0.05 for comparisons between four clusters 2, 3, 4 (red) and the healthy group for all pairwise comparison. *P* \> 0.05 for between Cluster 1 and the healthy group

Structural alterations in segmental airways were also captured between clusters (Table [3](#Tab3){ref-type="table"}). Tracheal bifurcation angle (*θ*) and circularity (*Cr*) measured in the sLUL were significantly reduced in Cluster 4. Cluster 1 was characterized by airway wall thickening (WT\*↑), whereas Clusters 3 and 4 were demonstrated by airway wall thinning (WT\*↓) and airway narrowing (*D*~h~\*↓). As summarized in Fig. [2](#Fig2){ref-type="fig"}, clusters were characterized by airway wall thickening-dominance (Cluster 1), increased tissue fraction at TLC with marginally increased emphysema (Cluster 2), proximal and peripheral airway narrowing (Cluster 3), and severe alterations of tracheal bifurcation angle (*θ*) and airway shape (*Cr*) on proximal airways as well as peripheral alterations (Cluster 4).Table 3Segmental airway features at specific regionsVariableRegionCluster 1\
(*N* = 100)Cluster 2\
(*N* = 80)Cluster 3\
(*N* = 141)Cluster 4\
(*N* = 85)*P* valueHealthy\
(*N* = 69)*θ*Trachea91.1(12.3)93.0(10.1)91.1(12.8)86.5(11.4)\<  0.00191.8(10.9)*Cr*sLUL0.961(0.014)0.959(0.015)0.956(0.012)0.943(0.021)\< 0.00010.958(0.013)WT\*sLUL0.571(0.035)0.564(0.034)0.546(0.035)0.536(0.042)\< 0.00010.561(0.036)*D*~h~\*sLUL0.273(0.028)0.256(0.029)0.236(0.024)0.230(0.033)\< 0.00010.264(0.031)*Cr*, WT\*, and *D*~h~\* were only presented at sLUL, but overall trends between clusters were consistent in different locations

Associations of imaging-based clusters with clinical features {#Sec8}
-------------------------------------------------------------

Clusters 1 and 2 were mostly populated in GOLD 0, 1 and 2 along with a lower BODE index, while Cluster 4 was mostly populated with GOLD 3 and 4 (stratum 4) with the highest BODE index (Table [4](#Tab4){ref-type="table"}). Cluster 2 showed the highest BMI (obese) among all clusters. Clusters 1 and 2 demonstrated similar post-bronchodilator FEV1/FVC values, but Cluster 2 had lower FEV1%predicted and FVC %predicted values compared with Cluster 1. Cluster 3 had significantly lower FEV1%predicted value and FEV1/FVC, along with preserved FVC value, whereas Cluster 4 had the lowest FEV1 and FVC % predicted values, along with the lowest FEV1/FVC.Table 4Demography, baseline (pre-bronchodilator) and maximal (post-bronchodilator) PFTs, in four imaging-based clustersCluster 1Cluster 2Cluster 3Cluster 4*P* value*N* = 100*N* = 80*N* = 141*N* = 85*Demography* GOLD (%) (0/1/2/3/4)62/23/14/1/057/20/20/2/06/24/51/16/32/0/12/46/40\< 0.0001 Strata (%) (2/3/4)62/37/157/40/26/74/192/12/86\< 0.0001 BODE index0.28(0.61)0.60(1.12)1.31(1.78)3.99(2.00)\<  0.0001 Sex (Female %)326434410.00015 Race (White/African-American/Other)88/6/675/20/591/4/584/12/50.0088 Age (yrs.)64.91(7.11)66.59(7.92)69.37(5.94)65.67(7.92)\<  0.0001 BMI (kg/m^2^)28.67(4.43)30.76(4.55)28.49(4.6)25.68(4.44)\<  0.0001*PFT Baseline lung function* ^a^ FEV1% predicted88(18)79(16)59(20)31(15)\<  0.0001 FVC % predicted97(14)88(14)85(18)71(19)\<  0.0001 FEV1/FVC × 10068(10)68(9)51(11)32(10)\<  0.0001*PFT Maximal lung function* ^b^ FEV1% predicted95(17)86(16)68(19)37(17)\<  0.0001 FVC % predicted101(14)91(14)94(17)80(20)\<  0.0001 FEV1/FVC × 10072(10)71(9)53(11)34(12)\<  0.0001Data presented as number (%) or mean (SD)^a^Pre-bronchodilator values^b^Post-bronchodilator values after six to eight puffs of albuterol. Full names of each variable were described in Abbreviations used. BODE indexes for 24 subjects were not available

The smoking pack-years were significantly greater in Clusters 3 and 4 than those of Clusters 1 and 2 (Table [5](#Tab5){ref-type="table"}). Cluster 4 showed higher associations with pulmonary/vascular condition, and chronic bronchitis, emphysema, and COPD diagnosed at baseline across all clusters. Shortness of breath during sleep was increased in Clusters 2 and 4. Fathers and mothers of subjects in Cluster 4 were likely to have COPD. The WBC counts were increased in Clusters 2--4, with increased neutrophils (Table [6](#Tab6){ref-type="table"}). Lymphocytes were reduced in Cluster 4. The proteolytic enzymes of matrix-metalloproteinases (MMPs) were reduced especially in Cluster 2. Based on the lowest CAT score and exacerbation, Cluster 1 subjects were likely asymptomatic (CAT\< 10) former smokers with the lowest exacerbation across all clusters. In contrast, Cluster 4 showed the highest CAT score with the lowest 6-min walk distance along with severe oxygen desaturation.Table 5Associations of symptoms and disease histories with cluster membershipCluster 1Cluster 2Cluster 3Cluster 4*P* value*N* = 100*N* = 80*N* = 141*N* = 85*Symptoms and disease History* Smoking pack-years at baseline48.09(22.27)48.21(25.3)57.64(27.4)54.44(22.9)0.001 History of pulmonary/vascular condition (%)241821390.0056 Chronic Bronchitis (%)101819310.005 Emphysema (%)28244576\<  0.0001 COPD diagnosed at baseline (%)40346488\<  0.0001 Chronic bronchitis diagnosed at baseline (%)11516190.061 Asthma (%)122019230.285 Wheezing and whistling in chest (%)465059590.167 Wheezing age (yrs.) (%)606778680.19 Sleep Apnea at baseline (%)282915170.106 Shortness of breath during sleep (%)6177170.012 Coronary artery disease6121570.101 Diabetes (%)121911140.452 Heart attack (%)156100.08 Congestive heart failure (%)12320.81*Genetic effect* Father had COPD (%)151422330.006 Mother had COPD (%)91212230.041Table 6Characteristics of biomarkers in four imaging-based clustersCluster 1Cluster 2Cluster 3Cluster 4*P* value*N* = 100*N* = 80*N* = 141*N* = 85*Blood/serum biomarkers* RBC distribution width (%)13.69(1.49)13.66(1.62)13.77(1.54)13.78(1.57)0.953 Total WBC count (N/μl)6203.8(1595.18)6773.08(1954.3)6907.27(1721.5)7330.24(2155.13)0.0005 Neutrophils% (%)59.74(8.48)61.17(9.35)62.12(8.32)63.5(11.2)0.044 Lymphocyte% (%)28.38(7.98)27.28(8.74)25.97(7.14)23.9(9.47)0.002 Monocyte% (%)7.97(2.43)7.72(2.44)8.3(2.55)8.06(2.71)0.432 Eosinophils% (%)3.29(2.12)3.18(1.98)2.85(1.62)2.64(1.73)0.071 Basophils% (%)0.68(0.41)0.59(0.41)0.65(0.52)0.57(0.56)0.321 Matrix metalloproteinase (MMP-3) (pg/mL)10.17(8.1)8.41(4.65)11.07(6.12)12.43(10.57)0.0082*Baseline CAT score* ^a^9.36(6.19)10.73(6.61)10.96(6.38)17.06(7.34)\<  0.0001*Exacerbations* Severe^b^0.08(0.34)0.25(1.11)0.23(0.7)0.84(1.61)\<  0.0001 Total^c^0.44(0.96)0.81(1.78)0.94(1.52)2.56(3.09)\<  0.0001 Total at baseline^d^0.16(0.44)0.32(0.87)0.21(0.53)0.66(0.92)\<  0.0001*Activity limitation* 6-min walk distance (m)459.23(84.5)431.4(91.71)412.76(113.09)338.5(114.57)\<  0.0001 Oxygen desaturation with 6-min walk (%)18173676\<  0.0001Kruskal-Wallis and chi-square tests were performed for continuous and categorical variables, respectively, and their *P* values were reported^a^CAT score range from 0 to 40, with higher scores indicating greater severity symptoms^b^Total count of exacerbations requiring ED visit or hospitalization since entering the study^c^Total count of exacerbations since entering the study^d^Total Exacerbations for baseline

We further associated the clusters with visual diagnostic assessments including COPD subtypes (CLE: Centrilobular; PSE: Paraseptal; PLE: Panlobular emphysema) as well as interstitial lung disease (ILD) by an experienced thoracic radiologist at the University of Iowa (Table [7](#Tab7){ref-type="table"}) because these subtypes might be associated with airway abnormalities \[[@CR27]\]. Cluster 4 was less likely related to ILD and had a significant increase of PLE. Subjects with PLE were not observed in Clusters 1 and 2. We analyzed longitudinal data of 169 available subjects among the current cohort of former smokers to quantify change of Emph%, i.e., emphysema progression index (ΔEmph%) between baseline and one-year follow-up. ΔEmph% is computed as the percentage of voxels within the lung less than − 950 HU and assesses the extend of emphysema (ΔEmph% ≥ 1% and ΔEmph% ± 0.5% are considered as rapid-progressors and non-progressors, respectively) \[[@CR28]\]. ΔEmph was marginal in Cluster 2 (Table [7](#Tab7){ref-type="table"}), whereas it was significantly higher in Cluster 4.Table 7Associations of visual diagnostics (VD) and of emphysema subtypes with cluster membershipCluster 1Cluster 2Cluster 3Cluster 4*P* value*Visual Diagnosis by Radiologist (VD)N* = 55*N* = 41*N* = 76*N* = 51 Bronchiectasis (%)453157620.018 Interstitial lung disease (ILD, %)253430100.030 Lung nodule (%)656873610.476*N* = 14*N* = 14*N* = 23*N* = 5 Ground glass opacities (GGO)93%100%95%60%0.023 Reticular opacities93%93%100%80%0.309 Honeycombing57%29%65%40%0.163*Emphysema subtypesN* = 51*N* = 31*N* = 74*N* = 49 CLE7.8%16.1%10.8%6.1%0.481 PSE9.8%12.9%00\<  0.005 PLE0000NS CLE + PSE82.4%67.7%85.1%65.3%\<  0.005 CLE + PLE00010.2%\<  0.005 PSE + PLE0000NS CLE + PSE + PLE004.1%18.4%\<  0.0001*Progression Index*  (ΔEmph% ≥ 1%) (Rapid-progressors)*N* = 51*N* = 46*N* = 50*N* = 2225%11%58%68%\<  0.001Kruskal-Wallis and chi-square tests were performed for continuous and categorical variables, respectively, and their *P* values were reportedKruskal-Wallis and chi-square tests were performed for continuous and categorical variables, respectively. Five hundred ninety-nine SPIROMICS subjects were used for progression index (169 former smokers were available)*CLE* Centrilobular, *PSE* Paraseptal, *PLE* Panlobular emphysema

Furthermore, we compared two different clusters-grouping derived from current smokers \[[@CR6]\] and former smokers, respectively (Table [8](#Tab8){ref-type="table"}). Overall CAT score and exacerbation histories of current smokers were greater than those of former smokers. WBC counts were not differentiable in current smokers-derived clusters because all clusters showed large numbers of WBC count. On the other hand, WBC count of former smokers-derived Cluster 1 was the smallest and it was increased as increasing the cluster membership of former smokers. On the contrary to the finding of WBC counts, former smokers demonstrated greater Emph and fSAD% than current smokers, based on kernel density estimation (KDE) plots (Fig. [4](#Fig4){ref-type="fig"}). The dispersed density distribution of current smokers may indicate the masking effect of CT-based measures of emphysema and small airway disease, compared to former smokers \[[@CR7]\]. The Emph% and fSAD% of former smokers (Table [2](#Tab2){ref-type="table"}) were especially increased in Clusters 3 and 4, as compared with counterparts of current smokers \[[@CR6]\].Table 8Comparison of major clinical and biomarkers between current and former smokersCurrent smokersCluster 1Cluster 2Cluster 3Cluster 4*P* valueTotal WBC count (N/μl)7153(2291)7353(2527)7110(1954)7073(2123)0.924Baseline CAT score13.17 (7.95)16.45 (9.54)13.78 (7.86)20.06 (7.86)\<  0.0001BMI (kg/m^2^)27.63(4.7)31.1(5.04)25.58 (4.76)23.65 (4.26)\<  0.0001Exacerbations Severe0.2(0.6)0.44(1.62)0.31(0.82)1.25(2.27)\<  0.0001 Total0.49(1.19)1.09(3.39)0.92(2.14)2.09(2.91)\<  0.0001 Total at baseline0.25(0.68)0.58(1.39)0.22(0.63)0.62(0.99)0.011 Oxygen desaturation with 6-min walk (%)14361441\<  0.0001 Post-bronchodilator values (FEV1/FVC × 100)74(9)68(13)63(11)44(12)\<  0.0001Former smokers Total WBC count (N/μl)6204(1595)6773(1954)6907.27 (1722)7330.24 (2155)0.005 Baseline CAT score9.36(6.19)10.73 (6.61)10.96 (6.38)17.06 (7.33)\<  0.0001 BMI (kg/m^2^)28.67 (4.43)30.76 (4.55)28.49 (4.60)25.68 (4.44)\<  0.0001Exacerbations Severe0.08(0.34)0.25(1.11)0.23(0.70)0.84(1.61)\<  0.0001 Total0.44(0.96)0.81(1.78)0.94(1.52)2.56(3.09)\<  0.0001 Total at baseline0.16(0.44)0.32(0.87)0.21(0.53)0.66(0.92)\<  0.0001 Oxygen desaturation with 6-min walk (%)18173776\<  0.0001 Post-bronchodilator values (FEV1/FVC × 100)72(10)71(9)53(11)34(12)\<  0.0001Kruskal-Wallis and chi-square tests were performed for continuous and categorical variables, respectively, and their *P* values were reportedFig. 4Kernel density estimation (KDE) plots with contour labels based on Emph% and fSAD% for current and former smokers

Decision tree analysis {#Sec9}
----------------------

We performed a decision tree analysis to construct a simple predictive model (Additional file [3](#MOESM3){ref-type="media"}: Figure S3) to classify former smokers. The data set was shuffled randomly into training (*n* = 324) and test sets (*n* = 82) and the accuracy was assessed on the test set. The model comprising 5 discriminant variables resulted in accuracy of 81%. These variables were β~tissue~^RV^ (Total), Jacobian (Total), β~tissue~^TLC^ (Total), *D*~h~\* (RMB) and ADI (Total).

We further evaluated an association between current and former smoker clusters by assessing the membership of former smokers in the decision tree of current smokers \[[@CR6]\] and vice versa. The classification accuracy for both cases was about 0.62 based on the confusion matrices (Additional file [4](#MOESM4){ref-type="media"}: Table S1). It can give an assessment for possible overlap between clusters of these two cohorts.

Discussion {#Sec10}
==========

In this study, we applied an unsupervised clustering method with an expanded set of imaging-based variables to former COPD smokers collected in the multicenter study of SPIROMICS. Four homogeneous clusters were derived within a former-smoker population, exhibiting distinct phenotypic characteristics and strong associations with clinically relevant COPD biomarkers. The imaging-based clusters can provide more information than the conventional PFT-based classification of COPD, such as stratum and GOLD criteria, because they explain structural and functional alterations at lobar and segmental levels. We also included parenchymal metrics including Emph%, fSAD%, tissue fractions at TLC and RV as well as segmental-level structural metrics including wall thickness and diameter of airway branches. The imaging and clinical phenotypes based on the clusters could be explained as follows.

Features of respective clusters {#Sec11}
-------------------------------

The cluster memberships can suggest possible phenotypes with distinct characteristic correlated with relevant clinical/biomarker measures for former COPD smoker.

Cluster 1: asymptomatic resistant smokers with preserved pulmonary function {#Sec12}
---------------------------------------------------------------------------

Cluster 1 showed preserved pulmonary function (FEV1/FVC = 0.72) at post bronchodilator and was mostly populated in GOLD stages 0 and 1. This cluster had a relatively low Emph% and fSAD% with structural and functional characteristics close to those of healthy controls. BODE index, exacerbation histories and WBC count of this cluster were relatively lower compared with other clusters. These characteristics along with CAT\< 10 and the lowest exacerbation among all clusters suggests that Cluster 1 belongs to asymptomatic resistant smokers. Cluster 1 imaging metrics were very close to those of healthy subjects. Airway wall thickening was the only abnormality in this cluster. A large population study, Multi-Ethnic Study of Atherosclerosis (MESA) \[[@CR29]\], reported that long-term smoking may contribute to airway wall thickening prior to the development of more severe imaging features of COPD.

Cluster 2: obese female individuals with preserved lung function and marginal emphysema {#Sec13}
---------------------------------------------------------------------------------------

Cluster 2 with the highest BMI and over-representation of women indicated clinical and epidemiological importance as reported by Castaldi et al. \[[@CR10]\] and Martinez et al. \[[@CR30]\]. Castaldi et al. \[[@CR10]\] derived four clusters with 10,192 subjects from COPDGene using several imaging-based metrics, e.g., Emph%, upper/lower ratio of Emph%, gas trapping, and PFT results acquired by a feature selection method. Note that our Cluster 2 is aligned with Cluster 2 of Castaldi et al. \[[@CR10]\] in high BMI, African-American and women-dominance. Cluster 2 showed the preserved pulmonary function (FEV/FVC = 0.71) close to Cluster 1, but the CAT score and exacerbation of this cluster was greater than that of Cluster 1. This group showed a noticeable increase of tissue fraction at TLC, and a decrease of emphysema index among clusters. This cluster included more CLE-only type while showing the lowest ΔEmph% among clusters. This finding is of interest because most studies showed that development of CLE is associated with severe abnormalities of the small airways, e.g. wall thickening. Thus, CLE may be more related to air-borne risk factors that cause airway inflammatory processes \[[@CR27]\]. Cluster 2 also showed the lowest value of MMPs among clusters. Ostridge et al. \[[@CR31]\] investigated the association between specific pulmonary MMPs and emphysema as these enzymes degrade the extracellular matrix and have been identified as potentially important in the development of emphysema \[[@CR31]\].

Cluster 3: older male individuals with increasing fSAD and emphysema {#Sec14}
--------------------------------------------------------------------

Unlike Clusters 1 and 2, Cluster 3 demonstrated a significant decrease of FEV1/FVC and FEV1% predicted values, but their FVC % predicted value remained in the normal range. This cluster was mostly populated in GOLD stages 2 and 3 with a significant increase in BODE index. From this cluster, Emph% and fSAD% in parenchymal regions were significantly increased, being similar with Cluster 4. Thus, this cluster showing airway narrowing without airway wall thinning, and normal circularity and skeletal structure (airway geometry) would be categorized as an intermediate cluster between less severe stage (Cluster 1) and more severe stage of COPD (Cluster 4).

Cluster 4: severe emphysema and fSAD individuals with severe structural alterations {#Sec15}
-----------------------------------------------------------------------------------

This cluster showed the highest Emph%, fSAD%, BODE index, WBC count and CAT score along with the lowest FEV1/FVC among all clusters. These characteristics along with structural and functional variables indicated that Cluster 4 belongs to severe symptomatic COPD subjects. The pattern of decreasing *D*~h~\* with increasing fSAD% (non-emphysematous air trapping) indicates severely narrowed status of both proximal and distal airways. In addition to airway narrowing, this group actually contains most of the significant structural and functional alterations. It is especially noted that prominent airway wall thinning and alteration of airway geometry change were only observed in this cluster. Assuming that this cluster is the most severe COPD group, alterations of airway features including airway wall thinning (WT\*), elliptic airway shape (*Cr*), and change of airway geometry (*θ*) may occur at the end stage of COPD.

Dominance of PLE with diffuse destruction in Cluster 4 along with its highest progression index among all clusters might be related to blood-borne mechanism rather than the possible air-borne mechanism in Cluster 2. These finding shows the possibility of two different pathogenetic mechanisms among subjects. In addition, Koo et al. \[[@CR32]\] studied WBC count as a biomarker and their associations with the severity of the disease. WBC count in former smokers has an increasing pattern from Cluster 1 to Cluster 4 (Table [6](#Tab6){ref-type="table"}) along with increasing CAT score and decreasing FEV1/FVC.

With previously analyzed current smokers \[[@CR6]\], the comparison for important clinical and biomarker measures between former and current smokers are shown in Table [8](#Tab8){ref-type="table"}. Overall, exacerbation has increasing pattern between clusters of former smokers with Cluster 1 and Cluster 4 with the lowest and highest, respectively. Cluster 2 for both current and former smokers has increased exacerbation compared to clusters 1 and 3 and might be related to the highest tissue fraction and possible inflammation in Cluster 2.

WBC count was lower in former smokers possibly due to the effect of smoking on the WBC \[[@CR6]\], which was also significantly elevated as increasing cluster membership. This result indicates that WBC count can serve as an important risk factor such as inflammation especially in former smokers. Furthermore, the CAT score and exacerbation histories were significantly higher in current smokers than in former smokers. An increase in inflammatory markers in current smokers relative to former smokers was contradictory to imaging-based features such as Emph% and fSAD% (Fig. [4](#Fig4){ref-type="fig"}). The smoking status could affect parenchymal inflammation, leading to an increase of CT density \[[@CR6], [@CR7]\]. Thus Emph% and fSAD% could be underestimated, if patients are on smoking. This confounding effect prevents from applying a clustering algorithm for former and current smokers due to the low Jaccard index (\< 0.7).

To assess a possible overlap between current and former smokers, we used the trained decision tree on current smokers to classify former smokers and vice versa; the classification accuracy for both cases was about 0.62 (the confusion matrices are reported in Additional file [4](#MOESM4){ref-type="media"}: Table S1). This result indicates that two clustering analyses between former and current smokers can be further used to investigate the difference in phenotypic characteristics of these cohorts. The impact of smoking status on cluster membership requires further investigation with larger cohorts as well as with longitudinal data to inspect disease progression and membership transition over time.

Conclusions {#Sec16}
===========

We performed a cross-sectional study to derive four unique imaging-based clusters in former smokers with COPD. The current cluster analysis can be used in conjunction with our previously reported cluster analyses in current smokers with COPD to assess the differences in smoking status (former vs current) in the COPD population and explore possible different phenotypes between these two groups.

Additional files
================

 {#Sec17}

Additional file 1:**Figure S1.** A scree plot: eigenvalues (magnitude of variances) according to the number of principal components for determining the optimal number of components. (DOCX 65 kb) Additional file 2:**Figure S2.** (a) Internal properties in different clustering methods to find the best clustering approaches as well as the optimal number of clusters; (b) Bootstrapping stability analysis between K-means and hierarchical clustering with 4 or 5 numbers of clusters. (DOCX 58 kb) Additional file 3:**Figure S3.** Predicting imaged-based cluster using only 5 important variables. Variables are β~tissue~^RV^ (Total), Jacobian (Total), β~tissue~^TLC^ (Total), *D*~h~\* (RMB) and ADI (Total) with 81% accuracy. (DOCX 59 kb) Additional file 4:**Table S1.** The confusion matrices to assess the possible overlap between current and former smoker clusters. Values are presented as the number of subjects (%). (DOCX 15 kb)
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